Papers
10
Total Citations
59
H-Index
5
About
Dr. Shun Wan is a rising leader in urologic oncology and robotic surgery, whose research systematically evaluates the comparative effectiveness of emerging surgical platforms. His work centers on three key areas: optimizing treatment for renal tumors, advancing prostate cancer surgery, and pioneering the adoption of novel robotic systems. Dr. Wan’s major contributions include providing high-level evidence that robot-assisted partial nephrectomy can match or surpass open surgery for complex renal masses (RENAL score ≥7), and demonstrating that percutaneous ablation offers a viable alternative to minimally invasive partial nephrectomy for T1 tumors. His impact is underscored by a growing body of highly cited meta-analyses—including a 2023 study on complex renal tumors (15 citations) and a 2024 comparison of Da Vinci vs. Hugo RAS for prostatectomy (12 citations). Notably, his 2025 network meta-analysis provides the first comprehensive comparison of four robotic systems (Da Vinci, KangDuo, Hugo, and Hinotori) in radical prostatectomy, showing comparable safety and oncologic outcomes across platforms. Dr. Wan’s work is essential reading for surgeons and researchers navigating the rapidly evolving landscape of robotic urologic surgery.
Research Focus
Key Achievements
Top Papers
- 1
- 2
- 3
- 4
- 5
- 6
- 7
- 8
- 9
- 10